Delhi High Court Orders Sun Pharma to Seek Approval Before Semaglutide Tablet Launch
The Delhi High Court has directed Sun Pharma to seek judicial approval before launching semaglutide tablets, following a patent infringement suit by Novo Nordisk. While Novo Nordisk's primary patent for injectable semaglutide expired in March, it holds a separate patent for the oral tablet formulation, which it claims Sun Pharma infringed. The court ordered Sun Pharma to apply for permission once it obtains a manufacturing license, after which the court will decide on further steps. Sun Pharma contested the court's jurisdiction and the patent claims.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is neutral (50/100). Lens Score 49/100.
Outlets measured: economictimes, mint. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (50–50/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
mint broke this story on 11 Aug, 02:30 pm. Other outlets followed.
- 1